RELESUUMAB (Reslizumab)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Mucolytics and stimulators of motor function of the respiratory tract

Included in the formulation
  • Sinqueiro
    concentrate d / infusion 
    Teva Pharmaceutical Enterprises Co., Ltd.     Israel
    • АТХ:

    R.03.D.X.08   RELESUUMAB

    Pharmacodynamics:

    Monoclonal antibody binds interleukin-5. This interrupts the processes of activation, growth and differentiation of eosinophils. As a result, the number of eosinophils is reduced and their survival is reduced. Consequently, the symptoms of bronchial inflammation subsided and bronchospasm is prevented.

    Pharmacokinetics:

    After intravenous administration, the maximum concentration in the blood plasma is reached at the end of the infusion. Metabolized by enzymatic proteolysis to amino acids.

    The half-life is 24 days.

    Indications:

    It is used to treat and prevent attacks of bronchial asthma and allergic rhinitis.

    ICD-10

    X.J30-J39.J30.1   Allergic rhinitis caused by pollen of plants

    X.J30-J39.J30.2   Other seasonal allergic rhinitis

    X.J30-J39.J30.3   Other allergic rhinitis

    X.J40-J47.J45   Asthma

    X.J40-J47.J45.0   Asthma with predominance of an allergic component

    Contraindications:

    Age to 2 years.

    Carefully:

    Pregnancy and lactation, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Intravenously slowly, for 30-50 minutes, 3 mg / kg weight every 4 weeks.

    The highest daily dose: 3 mg / kg body weight.

    The highest single dose: 3 mg / kg body weight.

    Side effects:

    Central and peripheral nervous system: agitation, asthenia, insomnia, anxiety, hallucinations, suicidal thoughts, tremor.

    Respiratory system: pain in the nasopharynx, infection of the upper respiratory tract.

    Hemopoietic system: decrease in clotting time, tendency to bleeding.

    The cardiovascular system: tachycardia.

    Digestive system: indigestion, diarrhea, pancreatitis.

    Musculoskeletal system: arthralgia, myalgia, convulsions.

    Dermatological reactions: nodosum and multiform erythema, rash.

    urinary system: enuresis in childhood.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    Not applicable for acute bronchospasm and asthmatic status.

    Instructions
    Up